phenprocoumon and coumarin

phenprocoumon has been researched along with coumarin* in 60 studies

Reviews

1 review(s) available for phenprocoumon and coumarin

Article	Year
Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms. Thrombosis research, 2015, Volume: 135, Issue:1 Numerous factors affect the response to vitamin K antagonists (VKA) including age, dietary vitamin K, other drugs, pharmacogenetics, and disease states. In antithrombotic guidelines, fever is mentioned as a factor that may increase response to VKA. The purpose of this article is to review the available evidence regarding the effect of fever on response to VKA, and to discuss possible mechanisms of this effect. We performed a search of the English literature from 1943 to June 2014, using the key words fever AND warfarin, acenocoumarol, phenprocoumon, coumarin anticoagulants and VKA; fever AND vitamin K dependent clotting factors II, VII, IX, and X. One animal investigation and 6 studies in humans suggest fever increases response to VKA, but one study did not find a significant effect. The magnitude of this effect is variable. Possible mechanisms for the increased effect of VKA associated with fever are increased catabolism of vitamin K dependent clotting factors, decreased vitamin K intake, and inhibition of VKA metabolism. More rigorous studies are needed to confirm that fever increases response to warfarin and other VKA. Topics: Acenocoumarol; Animals; Anticoagulants; Clinical Trials as Topic; Coumarins; Fever; Hemorrhage; Humans; International Normalized Ratio; Phenprocoumon; Rats; Risk Factors; Treatment Outcome; Vitamin K; Warfarin	2015

Article

Year

Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.

Thrombosis research, 2015, Volume: 135, Issue:1

Numerous factors affect the response to vitamin K antagonists (VKA) including age, dietary vitamin K, other drugs, pharmacogenetics, and disease states. In antithrombotic guidelines, fever is mentioned as a factor that may increase response to VKA. The purpose of this article is to review the available evidence regarding the effect of fever on response to VKA, and to discuss possible mechanisms of this effect. We performed a search of the English literature from 1943 to June 2014, using the key words fever AND warfarin, acenocoumarol, phenprocoumon, coumarin anticoagulants and VKA; fever AND vitamin K dependent clotting factors II, VII, IX, and X. One animal investigation and 6 studies in humans suggest fever increases response to VKA, but one study did not find a significant effect. The magnitude of this effect is variable. Possible mechanisms for the increased effect of VKA associated with fever are increased catabolism of vitamin K dependent clotting factors, decreased vitamin K intake, and inhibition of VKA metabolism. More rigorous studies are needed to confirm that fever increases response to warfarin and other VKA.

Topics: Acenocoumarol; Animals; Anticoagulants; Clinical Trials as Topic; Coumarins; Fever; Hemorrhage; Humans; International Normalized Ratio; Phenprocoumon; Rats; Risk Factors; Treatment Outcome; Vitamin K; Warfarin

2015

Trials

1 trial(s) available for phenprocoumon and coumarin

Article	Year
Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. Swiss medical weekly, 2013, Volume: 143 Prospective validation of two algorithms for the initiation of phenprocoumon treatment.. Inpatients with new-onset anticoagulation were randomised to one of two computer assisted dosing algorithms, or to a control arm. The primary outcome measure was the time to achieve therapeutic anticoagulation without overshooting (INR >4.0 within 10 days). Secondary outcomes included overshooting INR values, death, or bleeding within 30 days. In addition, predictors of the dosing algorithms for the loading dose and the maintenance dose including genetic parameters were reassessed.. 105 patients were randomised to arm A, 103 to arm B and 93 to the control arm. Arms A and B needed a median of 7 days to reach a therapeutic INR, arm C 6 days (p = 0.5). Overshooting INR was observed in 3.8%, 1.9% and 4.3% respectively (p = 0.6). Bleeding was found in 0%, 1.9%, and 5.4% (p = 0.06) and 30-day mortality was 0%, 1%, and 2.2% respectively (p = 0.2). VKORC1:c.-1639 G>A was associated with lower loading doses whereas VKORC1:c.-1453 G>A needed higher doses. VKORC1:c.-1639 G>A was also associated with lower maintenance doses.. Both algorithms allow safe initial dosing of phenprocoumon but they are not superior to anticoagulation by trained physicians. Dosing aids for coumarins with readily available clinical parameters may nevertheless be helpful for use in polymorbid hospitalised patients. Clinical data and the INR-response to treatment provides powerful information and delaying initiation of anticoagulation while awaiting genetic tests is not expected to increase drug safety. Topics: Aged; Algorithms; Anticoagulants; Confidence Intervals; Coumarins; Drug Dosage Calculations; Female; Genotype; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Polypharmacy	2013

Article

Year

Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon.

Swiss medical weekly, 2013, Volume: 143

Prospective validation of two algorithms for the initiation of phenprocoumon treatment.. Inpatients with new-onset anticoagulation were randomised to one of two computer assisted dosing algorithms, or to a control arm. The primary outcome measure was the time to achieve therapeutic anticoagulation without overshooting (INR >4.0 within 10 days). Secondary outcomes included overshooting INR values, death, or bleeding within 30 days. In addition, predictors of the dosing algorithms for the loading dose and the maintenance dose including genetic parameters were reassessed.. 105 patients were randomised to arm A, 103 to arm B and 93 to the control arm. Arms A and B needed a median of 7 days to reach a therapeutic INR, arm C 6 days (p = 0.5). Overshooting INR was observed in 3.8%, 1.9% and 4.3% respectively (p = 0.6). Bleeding was found in 0%, 1.9%, and 5.4% (p = 0.06) and 30-day mortality was 0%, 1%, and 2.2% respectively (p = 0.2). VKORC1:c.-1639 G>A was associated with lower loading doses whereas VKORC1:c.-1453 G>A needed higher doses. VKORC1:c.-1639 G>A was also associated with lower maintenance doses.. Both algorithms allow safe initial dosing of phenprocoumon but they are not superior to anticoagulation by trained physicians. Dosing aids for coumarins with readily available clinical parameters may nevertheless be helpful for use in polymorbid hospitalised patients. Clinical data and the INR-response to treatment provides powerful information and delaying initiation of anticoagulation while awaiting genetic tests is not expected to increase drug safety.

Topics: Aged; Algorithms; Anticoagulants; Confidence Intervals; Coumarins; Drug Dosage Calculations; Female; Genotype; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Polypharmacy

2013

Other Studies

58 other study(ies) available for phenprocoumon and coumarin

Article	Year
[Coumarin-induced necrotic purpura of the skin -- case report and review of the literature]. Praxis, 2012, Apr-25, Volume: 101, Issue:9 We report the case of a 28-year old woman with extensive red-black colored lesions of the skin on the left thigh, which appeared without trauma. The disease arrived during longterm coumarin therapy because of a deep vein thrombosis and an antiphospholipid syndrome. After consideration of the differential diagnoses and due to the typical clinical picture we made the diagnosis of coumarin necrosis. We review the clinical and therapeutic features for this rare complication. Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation Tests; Coumarins; Diagnosis, Differential; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Leg Dermatoses; Long-Term Care; Necrosis; Phenprocoumon; Skin; Venous Thrombosis; Vitamin K Deficiency	2012
Thromboembolism and coumarin overdosage in a 19-year-old female: impact of pharmacogenetics. Clinical genetics, 2010, Volume: 78, Issue:5 Topics: Coumarins; Drug Overdose; Female; Humans; Iliac Vein; International Normalized Ratio; Pharmacogenetics; Phenprocoumon; Prothrombin; Thromboembolism; Vena Cava, Inferior; Young Adult	2010
Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenetics and genomics, 2005, Volume: 15, Issue:2 Vitamin K is an essential cofactor for the synthesis of several blood coagulation factors. It has been suggested that the apolipoprotein E (ApoE) genotype has profound effects on vitamin K status. Therefore, we investigated whether this common genetic polymorphism influenced dose requirements and effects of coumarin anticoagulants.. We did a cohort study in 1637 patients from an outpatient anticoagulation clinic treated with acenocoumarol or phenprocoumon.. To attain the same level of anticoagulation, patients with genotype epsilon4/epsilon4 and genotype epsilon3/epsilon4 required respectively 3.4 mg (95%CI: -6.0 to -0.9) and 0.8 mg (95%CI: -1.6 to 0.1) acenocoumarol per week less than patients with genotype epsilon3/epsilon3. Patients homozygous for the epsilon2 allele required 3.5 mg (95%CI: 0.1 to 6.9) acenocoumarol per week more than patients with genotype epsilon3/epsilon3. The acenocoumarol maintenance dose showed a gene dose effect of the epsilon4 allele, but not of the epsilon2 allele. No significant dose difference was observed for phenprocoumon, possibly because of low numbers.. The ApoE genotype affects the dose requirements of acenocoumarol. Topics: Acenocoumarol; Aged; Alleles; Anticoagulants; Apolipoproteins E; Blood Coagulation; Cohort Studies; Coumarins; Female; Genotype; Homozygote; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Time Factors; Vitamin K	2005
[The clinical course of coumarin-induced necrosis]. Deutsche medizinische Wochenschrift (1946), 1991, Aug-30, Volume: 116, Issue:35 In three patients painful reddening of a well-circumscribed area of the skin occurred within five days of starting anticoagulant treatment with phenprocoumon (Marcumar), and within a short time it developed into a full-blown picture of coumarin necrosis. The indication for phenprocoumon was, in the first patient (a 29-year-old mother lying-in after her second child had been born) an increased platelet count and the presence of high risk factors for thromboembolism. In the second patient (25-year-old man) and the third one (45-year-old woman) it was secondary prophylaxis after pulmonary embolus and deep-vein thrombosis, respectively. All three patients were very obese and had a drug allergy, as well as other allergies (bronchial asthma in Cases 1 and 2; allergic rhinitis in Case 3). Phenprocoumon was at once discontinued in all three patients and low-dose heparin administration (Cases 1 and 3) or dextran infusion (Case 2: heparin intolerance) started. All three needed excision of the necrotic tissue with grafting to the skin defect. The coexistence of obesity and allergic diathesis may thus present an especially high risk for coumarin necrosis. Topics: Adult; Coumarins; Drug Hypersensitivity; Drug Therapy, Combination; Female; Heparin; Humans; Middle Aged; Necrosis; Obesity; Phenprocoumon; Pulmonary Embolism; Risk Factors; Skin Diseases; Thrombophlebitis; Time Factors	1991
New anticoagulant for oral use-3-(1'-phenylpropyl)-4 hydroxycoumarin (liquamar); its evaluation for short-term therapy. Journal of the American Medical Association, 1959, Jul-11, Volume: 170, Issue:11 Topics: 4-Hydroxycoumarins; Anticoagulants; Coumarins; Phenprocoumon	1959
A new coumarin, 3-(1'-phenylpropyl)-4-hydroxycoumarin (marcumar). Canadian Medical Association journal, 1958, Jan-01, Volume: 78, Issue:1 Topics: 4-Hydroxycoumarins; Coumarins; Phenprocoumon	1958
[Experiences with a general thrombosis preventative with a report of results of more than 3000 treatments with marcumar]. Bruns' Beitrage zur klinischen Chirurgie, 1958, Volume: 196, Issue:1 Topics: Anticoagulants; Coumarins; Humans; Phenprocoumon; Thromboembolism; Thrombosis	1958
Phenoprocoumon (marcumar). I. An agent for short-term anticoagulant therapy. The American journal of cardiology, 1958, Volume: 2, Issue:1 Topics: Anticoagulants; Coumarins; Humans; Phenprocoumon	1958
[Extensive tissue necrosis after postoperative prophylaxis of an embolism by marcoumar]. Geburtshilfe und Frauenheilkunde, 1958, Volume: 18, Issue:4 Topics: Coumarins; Disease; Embolism; Humans; Phenprocoumon; Thigh	1958
[Microscopic studies on the effect of the anticoagulant marcumar on vascular permeability]. Folia haematologica; internationales Magazin fur Blutforschung, 1958, Volume: 2, Issue:4 Topics: Anticoagulants; Capillary Permeability; Coumarins; Humans; Phenprocoumon	1958
[Intravenous anticoagulant therapy with marcumar]. Arztliche Wochenschrift, 1958, Sep-05, Volume: 13, Issue:35-36 Topics: Anticoagulants; Coumarins; Phenprocoumon	1958
[Coagulation disorders caused by abuse in the use of marcoumar]. Helvetica medica acta, 1958, Volume: 25, Issue:4 Topics: Blood Coagulation Disorders; Coumarins; Hemorrhagic Disorders; Phenprocoumon	1958
[The indirect action anticoagulant marcumar in the control of thrombosis]. Nederlands tijdschrift voor geneeskunde, 1958, Nov-15, Volume: 102, Issue:46 Topics: Anticoagulants; Coumarins; Phenprocoumon; Thrombosis	1958
[Anticoagulant therapy with marcumar]. Die Medizinische, 1957, Feb-16, Issue:7 Topics: Anticoagulants; Coumarins; Phenprocoumon	1957
Effect of oral anticoagulant (marcumar) on prothrombin and related components in blood coagulation. Circulation research, 1957, Volume: 5, Issue:3 Topics: Anticoagulants; Blood Coagulation; Coumarins; Humans; Phenprocoumon; Prothrombin	1957
[Effect of marcoumar therapy on completely breast-fed children]. Schweizerische medizinische Wochenschrift, 1957, May-25, Volume: 87, Issue:21 Topics: Breast Feeding; Coumarins; Phenprocoumon	1957
[Protective effect of heparin during acute poisoning with marcumar]. Gazzetta medica italiana, 1957, Volume: 116, Issue:6 Topics: Coumarins; Heparin; Phenprocoumon	1957
[Effects of marcumar therapy in breast-fed children]. Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie, 1957, Volume: 144, Issue:1 Topics: Breast Feeding; Child; Coumarins; Humans; Infant; Infant, Newborn; Phenprocoumon	1957
Experience with the anticoagulant, marcumar. Annals of internal medicine, 1957, Volume: 47, Issue:4 Topics: Anticoagulants; Coumarins; Phenprocoumon	1957
Anticoagulant studies with dicoumarol and marcoumar; control achieved and applications. The New Zealand medical journal, 1957, Volume: 56, Issue:315 Topics: Anticoagulants; Coumarins; Dicumarol; Humans; Phenprocoumon; Thromboembolism	1957
[Hyaluronidase-like effect of marcumar in vivo]. Gazzetta medica italiana, 1956, Volume: 115, Issue:1 Topics: Coumarins; Hyaluronoglucosaminidase; Phenprocoumon	1956
[Inhibiting effect of heparin on hyaluronidase-like effect of marcumar]. Minerva medica, 1956, Jan-31, Volume: 47, Issue:9 Topics: Coumarins; Heparin; Humans; Hyaluronoglucosaminidase; Phenprocoumon	1956
[Marcoumar treatment of thromboembolic conditions]. Ugeskrift for laeger, 1956, Jan-12, Volume: 118, Issue:2 Topics: Coumarins; Phenprocoumon; Thromboembolism	1956
[Protective action of vitamin E on lesions caused by marcoumar]. Acta vitaminologica, 1956, Volume: 10, Issue:1 Topics: Coumarins; Phenprocoumon; Poisoning; Vitamin E	1956
[Experience with marcumar, a new prothrombopenic agent similar to coumarin]. Revista medica de Chile, 1956, Volume: 84, Issue:6 Topics: Coumarins; Phenprocoumon	1956
The effect of the administration of the anticoagulant marcumar on the blood coagulation mechanisms. Henry Ford Hospital medical bulletin, 1956, Volume: 4, Issue:4 Topics: Anticoagulants; Blood Coagulation; Coumarins; Phenprocoumon	1956
[Prevention of thromboembolism after gynecological surgery with marcumar, a coumarin derivative]. Zentralblatt fur Gynakologie, 1956, Aug-25, Volume: 78, Issue:34 Topics: Coumarins; Female; Genitalia; Genitalia, Female; Gynecologic Surgical Procedures; Humans; Phenprocoumon; Thromboembolism	1956
Marcumar, a new anticoagulant. Revue d'hematologie, 1955, Volume: 10, Issue:2 Topics: Anticoagulants; Coumarins; Phenprocoumon	1955
[Tromexan and marcoumar in anticoagulant therapy; micromethod for determination of prothrombin-proconvertin activity]. Ugeskrift for laeger, 1955, Jul-07, Volume: 117, Issue:27 Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Coumarins; Ethyl Biscoumacetate; Factor VII; Humans; Phenprocoumon; Prothrombin; Thrombosis	1955
[Behavior of hematic fibrinogen during treatment with marcoumar and with marcoumar and vitamin K; clinical and experimental aspects]. Archivio per le scienze mediche, 1955, Volume: 99, Issue:2 Topics: Antifibrinolytic Agents; Coagulants; Coumarins; Fibrinogen; Hemostatics; Heparin Antagonists; Humans; Phenprocoumon; Vitamin K	1955
Anticoagulant studies with marcoumar, a new coumarin derivative. British medical journal, 1955, Oct-15, Volume: 2, Issue:4945 Topics: Anticoagulants; Coumarins; Phenprocoumon; Research	1955
[Effect of 3-(1-phenylpropyl)-4-hydroxycoumarin (marcumar) on the functional, morphological and histochemical characteristics of blood platelets and megakaryocytes; experimental research]. Haematologica, 1955, Volume: 39, Issue:6 Topics: 4-Hydroxycoumarins; Blood Platelets; Cell Count; Coumarins; Humans; Megakaryocytes; Phenprocoumon	1955
[Anticoagulant therapy with marcoumar; with criticism of ambulant use]. Die Medizinische, 1955, Feb-19, Volume: 8 Topics: Anticoagulants; Coumarins; Phenprocoumon; Social Behavior	1955
[A new medicamentous incompatibility; thiomerin and marcoumar]. Schweizerische medizinische Wochenschrift, 1955, Feb-05, Volume: 85, Issue:6 Topics: Coumarins; Diuretics; Drug Incompatibility; Organomercury Compounds; Phenprocoumon	1955
[Experiences with a new anticoagulant (marcoumar)]. Wiener medizinische Wochenschrift (1946), 1955, Jan-08, Volume: 105, Issue:1 Topics: Anticoagulants; Blood Coagulation; Coumarins; Phenprocoumon; Prothrombin Time	1955
[Ambulant treatment of thrombophlebitic processes with "marcoumar" Roche]. Dermatologica, 1955, Volume: 110, Issue:1 Topics: Coumarins; Humans; Phenprocoumon; Thrombophlebitis	1955
[Comparative studies of blood coagulation in the treatment of thrombophlebitis with marcoumar and panthesin hydergin]. Wiener klinische Wochenschrift, 1955, May-13, Volume: 67, Issue:19 Topics: Aminobenzoates; Blood Coagulation; Coumarins; Ergot Alkaloids; Leucine; para-Aminobenzoates; Phenprocoumon; Thrombophlebitis	1955
[Experience with the anticoagulants marcumar and liquemin in gynecology]. Zentralblatt fur Gynakologie, 1955, Volume: 77, Issue:7 Topics: Anticoagulants; Coumarins; Female; Genital Diseases, Female; Gynecology; Heparin; Humans; Phenprocoumon	1955
[Vitamin K1-therapy in marcoumar hemorrhages]. Arztliche Wochenschrift, 1955, Apr-15, Volume: 10, Issue:15-6 Topics: Antifibrinolytic Agents; Coumarins; Hemorrhage; Humans; Naphthoquinones; Phenprocoumon; Retinoids; Vitamin K; Vitamin K 1	1955
[Anticoagulant prophylaxis by marcumar in gynecology and obstetrics]. Gazzetta medica italiana, 1955, Volume: 114, Issue:4 Topics: Anticoagulants; Coumarins; Female; Genital Diseases, Female; Gynecologic Surgical Procedures; Gynecology; Humans; Obstetric Surgical Procedures; Obstetrics; Phenprocoumon; Pregnancy	1955
[Anticoagulant prophylaxis with marcoumar in the puerperium]. Minerva ginecologica, 1955, Apr-30, Volume: 7, Issue:8 Topics: Anticoagulants; Coumarins; Female; Humans; Phenprocoumon; Postpartum Period; Thromboembolism	1955
[Clinical study of the anticoagulant 3-(1-phenylpropyl)-4-hydroxycoumarin or marcoumar and of its antidote, vitamin K1]. Minerva ginecologica, 1954, Jan-31, Volume: 6, Issue:2 Topics: 4-Hydroxycoumarins; Anticoagulants; Antidotes; Coumarins; Female; Hemostatics; Humans; Phenprocoumon; Prothrombin Time; Thrombophlebitis; Vitamin K; Vitamin K 1	1954
[Reports on clinical experiments with a new coumarin derivative (marcoumar)]. Munchener medizinische Wochenschrift (1950), 1954, Feb-05, Volume: 96, Issue:6 Topics: Coumarins; Humans; Phenprocoumon	1954
[The therapeutic use of a new anticoagulant, marcoumar]. Klinische Medizin; osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin, 1954, Feb-01, Volume: 9, Issue:2 Topics: Anticoagulants; Coumarins; Myocardial Infarction; Phenprocoumon; Thromboembolism; Thrombophlebitis	1954
[Thrombosis prophylaxis with marcoumar in puerperium and the state of health of the infant]. Schweizerische medizinische Wochenschrift, 1954, Apr-17, Volume: 84, Issue:16 Topics: Anticoagulants; Coumarins; Female; Health; Humans; Phenprocoumon; Postpartum Period; Thrombosis	1954
[Marcoumar in specific prevention of thrombosis]. Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie, 1954, Volume: 137, Issue:4 Topics: Anticoagulants; Coumarins; Female; Genitalia; Genitalia, Female; Humans; Phenprocoumon; Postpartum Period; Thrombosis	1954
[Marcoumar in general prevention of puerperal thrombosis]. Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie, 1954, Volume: 137, Issue:4 Topics: Anticoagulants; Coumarins; Female; Humans; Phenprocoumon; Postpartum Period; Puerperal Disorders; Thromboembolism	1954
[Clinical experience with the new anticoagulant marcoumar]. Praxis, 1954, Apr-15, Volume: 43, Issue:15 Topics: Anticoagulants; Coumarins; Phenprocoumon	1954
[Marcoumar and intermittent attack therapy]. Deutsche medizinische Wochenschrift (1946), 1954, Jun-11, Volume: 79, Issue:24 Topics: Animals; Antifibrinolytic Agents; Behavior, Animal; Coumarins; Humans; Naphthoquinones; Phenprocoumon; Vitamin K	1954
A comparative study of marcumar, tromexan and dicumarol, determination of plasma levels and prothrombin times after intravenous injection. Schweizerische medizinische Wochenschrift, 1954, Jul-17, Volume: 84, Issue:29 Topics: Blood; Coumarins; Dicumarol; Ethyl Biscoumacetate; Injections, Intravenous; Phenprocoumon; Plasma; Prothrombin Time	1954
Marcumar [3-(1'-phenylpropyl)-4-hydroxycoumarin]; a new anticoagulant. Circulation, 1954, Volume: 10, Issue:5 Topics: 4-Hydroxycoumarins; Anticoagulants; Coumarins; Phenprocoumon	1954
[Clinical studies on the new anticoagulant, marcoumar, and its antagonist, konakion (vitamin K1)]. Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie, 1954, Volume: 138, Issue:3 Topics: Anticoagulants; Antifibrinolytic Agents; Coumarins; Female; Genitalia; Genitalia, Female; Humans; Hypoprothrombinemias; Phenprocoumon; Postpartum Period; Prothrombin; Thrombophlebitis; Vitamin K; Vitamin K 1	1954
[Anticoagulant therapy with marcumar]. Munchener medizinische Wochenschrift (1950), 1954, Apr-02, Volume: 96, Issue:14 Topics: Anticoagulants; Coumarins; Phenprocoumon; Thromboembolism	1954
[Experiences with thrombosis prophylaxis with marcoumar]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1954, Volume: 25, Issue:12 Topics: Anticoagulants; Coumarins; Humans; Phenprocoumon; Thrombosis	1954
[Experimental research on the anticoagulant marcoumar (3-(1-phenyl-propyl)-4-hydroxy-coumarin) and its antagonist konakion (synthetic vitamin K1)]. Schweizerische medizinische Wochenschrift, 1953, May-16, Volume: 83, Issue:20 Topics: Anticoagulants; Capillaries; Cardiovascular System; Coumarins; Phenprocoumon; Prothrombin Time; Vitamin K 1	1953
[A new highly active anticoagulant with prolonged effect (marcoumar)]. Schweizerische medizinische Wochenschrift, 1953, May-16, Volume: 83, Issue:20 Topics: Anticoagulants; Coumarins; Heparin Antagonists; Humans; Infarction; Lung; Myocardial Infarction; Phenprocoumon; Pulmonary Infarction; Thrombosis; Vitamin K	1953
[Marcumar, 3-1-phenylpropyl-4-oxy-coumarin, a new superdicumarol]. Arztliche Forschung, 1953, Volume: 7, Issue:6 Topics: Coumarins; Phenprocoumon	1953
[The antithrombotic significance of a new coumaria derivative, marcoumar]. Die Medizinische, 1953, Oct-31, Volume: 44 Topics: Coumarins; Phenprocoumon	1953